Acelyrin, a California biotech focused on immunology and inflammatory disease, announced Tuesday that its experimental drug for a common skin disorder succeeded in a late-stage clinical trial.
That’s the kind of news that’s usually accompanied by plans to apply for regulatory approval to market a new therapy. But the results didn’t show a clear edge over competing products on the market or in development. And Acelyrin said it is halting further investment in the program amid a broader pivot in the company’s priorities that includes sizable layoffs.
The company announced in a press release that it doesn’t plan to invest further in developing izokibep, an injectable anti-inflammatory treatment, as a treatment for the skin disorder hidradenitis suppurativa, or for psoriatic arthritis. Instead, the biotech plans to focus on an experimental antibody treatment for thyroid eye disease.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect